Radius Pharmaceuticals, Inc. announced the appointment of Renata Sklodowska, M.D. as Senior Vice President, Medical Operations.
BOSTON, MA / ACCESSWIRE / June 25, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused on bone health and related areas, announced the appointment of Renata Sklodowska, M.D. as Senior Vice President, Medical Operations. Dr. Sklodowska joins Radius with over fifteen years of clinical development, regulatory, and medical affairs experience. She will report to Scott Briggs, Chief Executive Officer, and will oversee Medical Operations including Medical Affairs, Regulatory Affairs, and Pharmacovigilance (PV).
“I am very pleased to welcome Renata to our Executive Leadership Team at Radius,” said Scott. “Renata’s extensive pharmaceutical industry experience, as well as her strong leadership track record in global medical and scientific affairs, will be extremely valuable as Radius continues to build its presence in bone health and related areas. Of particular importance will be Renata’s strong patient-focus and ability to build alliances with medical, scientific, and patient communities to support our efforts with TYMLOS® and BINOSTO®.”
Dr. Sklodowska is an accomplished international pharmaceutical and biotech executive with Medical and Scientific Affairs expertise,as well as commercial experience. Her tenure includes more than fifteen years in the rare diseases area, including Endocrinology, with proven success preparing and supporting successful product launches as well as managing product portfolios. Dr. Sklodowska has an established history leading Medical Affairs activities for development stage and marketed drugs and a tested ability to create, train, and lead cross-functional teams to attain business objectives. Dr. Sklodowska has established global PV systems and provided oversight for the PV, drug safety, and risk management activities for numerous marketed products. As part of her responsibilities, she will also provide important scientific and medical expertise and guidance to support therapeutic area and product assessments behind business development efforts at Radius.
“I look forward to joining the Radius team and applying my years of experience to build upon the company’s successes to date, and to not only support TYMLOS® and BINOSTO®, but to also provide medical and strategic insight to explore opportunities to expand the Radius portfolio over time,” stated Dr. Sklodowska.
Prior to joining Radius, Dr. Sklodowska held several leadership positions in clinical development and medical affairs at biotech and global pharmaceutical companies, having most recently served as Vice President of Medical Affairs at F2G and Recordati Rare Diseases. Dr. Sklodowska received her Doctor of Medicine degree from the Medical University of Bialystok, Poland where she was also an attending physician.
About Radius:
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also recently announced an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company’s presence in bone health.
Contact:
Sara Goldberg: Head of Communications
Email: corporatecommunications@radiuspharm.com
Phone: +1 (631) 379-8374
SOURCE: Radius Health, Inc.
View the original press release on accesswire.com
